Abattis Bioceuticals (EM)【ATTBF】銘柄情報

Abattis Bioceuticals Corporation (EM) (ATTBF) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.000001

( - )

買値

0.00

売値

0.00

出来高

0.00 日の範囲 0.00

0.000001 52 週間の範囲 0.0001

時価総額

476.054

前日終値

0.000001

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 48,644

発行済株式数

476,054,139

配当利回り

PER

-0

1 株当たり利益 (EPS)

-0.01

歳入

356.88k

純利益

-3.04M

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid... Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada. 詳細を表示

セクター

Healthcare

業界

Pharmaceuticals

ウェブサイト

www.abattis.com

本社

Vancouver, Canada

設立

1997

Abattis Bioceuticals Corporation (EM) is listed in the Healthcare sector of the その他OTC with ticker ATTBF. The last closing price for Abattis Bioceuticals (EM) was US$0. Over the last year, Abattis Bioceuticals (EM) shares have traded in a share price range of US$ 0.000001 to US$ 0.0001.

Abattis Bioceuticals (EM) currently has 476,054,139 shares in issue. The market capitalisation of Abattis Bioceuticals (EM) is US$476.05 . Abattis Bioceuticals (EM) has a price to earnings ratio (PE ratio) of -0.00.

S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports

S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports PR Newswire NEW YORK, March 25...

ANALYST REPORTS ON COMPANIES ANNOUNCING GAME CHANGING DEVELOPMENTS

Burton, MI - October 02, 2014 - InvestorsHub NewsWire - Anavex Life Sciences Corp. (OTCQB: AVXL) is a clinical-stage biopharmaceutical...

OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX®

OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX® PR Newswire NEW YORK, July 11, 2014 NEW YORK, July 11, 2014 /PRNewswire/ -- OTC Markets...

Industrial Hemp and Medical Marijuana Industry Gather for GreenRush Financial Conference in Vancouver

VANCOUVER,B.C., May 5, 2014 (GLOBE NEWSWIRE) -- A hundred and fifty years ago, Harry Barr's (President and CEO of Next Gen Metals) (CSE:N) (OTC...

Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project

Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project Sponsorship will fund completion of...

Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resist...

Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance PR...

Abattis Signs LOI With Crudessence Kombucha Inc. To License Infused, Blended Kombucha Tea

Abattis Signs LOI With Crudessence Kombucha Inc. To License Infused, Blended Kombucha Tea PR Newswire VANCOUVER, British Columbia, March 6, 2013...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	1.0E-6	1.0E-6	1.0E-6	500	1.0E-6	CS
4	0	0	1.0E-6	5.0E-6	1.0E-6	39112	1.0E-6	CS
12	0	0	1.0E-6	0.0001	1.0E-6	49675	1.0E-6	CS
26	0	0	1.0E-6	0.0001	1.0E-6	97657	1.0E-6	CS
52	-9.0E-6	-90	1.0E-5	0.0001	1.0E-6	72626	1.19E-6	CS
156	0	0	1.0E-6	0.000134	1.0E-6	39116	1.16E-6	CS
260	-0.013049	-99.9923371648	0.01305	0.0175	1.0E-6	84635	0.00565009	CS